Camrelizumab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Squamous Cell Carcinoma have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Camrelizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Camrelizumab (Airuika) is a humanized monoclonal antibody acts as immunomodulatory agent. It is formulated as solution for intravenous route. Camrelizumab is indicated as third-line treatment for recurrent or refractory classical hodgkin’s lymphoma, advanced hepatocellular carcinoma patients with oxaliplatin system chemotherapy, combined with pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, non-resectable locally advanced or metastatic first-line treatment of non-squamous non-small cell lung cancer (NSCLC), locally advanced or metastatic esophageal squamous cell carcinoma patients who have previously received first-line chemotherapy and whose disease has progressed or become intolerable and for the treatment of patients with advanced nasopharyngeal carcinoma who had disease progression after previous second-line and above chemotherapy or intolerable treatment.
Camrelizumab (SHR-1210) is under development for the treatment of advanced penile cancer, gestational trophoblastic neoplasia, advanced or metastatic extrapulmonary neuroendocrine carcinomas, squamous cancer of nasal cavity and paranasal sinuses, advanced liver cancer, human epidermal growth factor receptor 2 positive breast cancer (HER2+ breast cancer), gastric cancer, esophageal cancer, gastroenteropancreatic neuroendocrine carcinoma, locally advanced head and neck squamous cell carcinoma, advanced androgen resistant prostate cancer, gestational trophoblastic neoplasia, advanced or metastatic esophageal squamous cell cancer, advanced chordoma, unresectable urothelial carcinoma of the renal pelvis, ureter, bladder, or urethra, advanced neuroendocrine tumors, glioblastoma multiforme, oral squamous cell carcinoma, advanced cervical neuroendocrine carcinoma (NEC), hypopharyngeal cancer, non-muscle invasive bladder cancer, relapsed or refractory diffuse large B cell lymphoma and follicular lymphoma, ALK-negative lung adenocarcinoma, relapsed or metastatic thyroid poorly differentiated or undifferentiated carcinoma, metastatic acral melanoma, advanced lung sarcomatoid carcinoma, metastatic biliary tract cancer, muscle-invasive bladder urothelial carcinoma, gastroesophageal junction adenocarcinoma, rectal cancer, metastatic triple-negative breast cancer, gastric cancer, recurrent or metastatic head and neck squamous cell carcinoma, gastroesophageal junction adenocarcinoma, esophageal cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, liver cancer, osteosarcoma, bile duct cancer, metastatic hepatocellular carcinoma, pancreatic cancer, soft tissue sarcoma, small-cell lung cancer, cervical cancer, renal cell carcinoma, transitional cell carcinoma, endometrial cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, metastatic colorectal cancer, melanoma, triple negative breast cancer, gynecological cancer, urinary tract cancer, anaplastic large cell lymphoma, advanced right-sided colon cancer, angioimmunoblastic T-Cell Lymphoma, peripheral T-Cell Lymphomas, metastatic periampulle cancer, bile duct cancer, gallbladder cancer, gastrointestinal tract cancer, relapsed or refractory extranodal NK/T cell lymphoma, papillary thyroid cancer, medullary thyroid cancer, synovial sarcoma, undifferentiated pleomorphic sarcoma, malignant fibrous histiocytoma, pleomorphic rhabdomyosarcoma, round cell liposarcoma, myxiod liposarcoma, malignant peripheral nerve sheath tumors, relapsed/refractory CD30+ lymphoma, naso-ocular related tumors, HER2 negative breast cancer, metastatic mucosal melanoma of head and neck (oral cavity, oropharynx, hypopharynx, or larynx) and solid tumor.
It was also under development for the treatment of solid tumors including metastatic colorectal cancer, endometrial cancer, thymic carcinoma, malignant pleural mesothelioma, follicular thyroid cancer and metastatic biliary tract cancer.
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US, and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
For a complete picture of Camrelizumab’s drug-specific PTSR and LoA scores, buy the report here.